Lipidor AB entered an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. The study is expected to begin 1Q21 with final reporting in 1Q22. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray-based AKVANO technology. An agreement has now been concluded with Cadila Pharmaceuticals for the implementation of the study. The Phase III study is expected to enr...